Akademik Veri Yönetim Sistemi
İzmir Katip Çelebi Üniversitesi Sağlık Bilimleri Fakültesi Dergisi, cilt.10, sa.3, ss.1-9, 2025 (Hakemli Dergi)
Objective: We investigated the effects of Thymoquinone in combination with Nivolumab on experimental renal cell cancer models. Thymoquinone
is a bioactive component extracted from Nigella sativa seeds, Thymoquinone has anti-inflammatory, antioxidant, and anti-tumor properties
against various cancers. Material and Methods: The effect of Thymoquinone and Nivolumab were analyzed using cell line Renca with 3-(4,5-
dimetiltiyazol-. 2-yl)-2,5-difeniltetrazolium-bromure and Annexin V + propidium iodure assays. Renca cells were subcutaneously injected into 8-
week-old male C57BL/6 mice. Groups were designed as control, Thymoquinone, Nivolumab, Thymoquinone+Nivolumab. Tumor tissues were
analyzed for apoptosis/necrosis rates, expression of immunomarkers and ribonucleidacid expression at significance level of p <0.05. Results:
The results showed that Thymoquinone had anti-tumor effects both in-vitro and in-vivo. The combination treatment with Nivolumab led to an
increase in immune mediated tumor cell death, resulting in significant necrosis or complete response to therapy in the tumor tissue.
Conclusion: It has been concluded that thymoquinone has an anti-tumor effect on renal cell carcinoma and that Nivolumab enhances the effects
of immune cell apoptosis has been concluded. Additionally, there are no side effects on other organs when used alone or in combination.
Keywords: Renal Cell Cancer, Thymoquinone, Immune checkpoint inhibitors.